Lin Lilie L, Lakomy David S, Chiao Elizabeth Y, Strother Robert M, Wirth Meg, Cesarman Ethel, Borok Margaret, Busakhala Naftali, Chibwesha Carla J, Chinula Lameck, Ndlovu Ntokozo, Orem Jackson, Phipps Warren, Sewram Vikash, Vogt Samantha L, Sparano Joseph A, Mitsuyasu Ronald T, Krown Susan E, Gopal Satish
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dartmouth Geisel School of Medicine, Hanover, NH.
JCO Glob Oncol. 2020 Jul;6:1134-1146. doi: 10.1200/GO.20.00153.
The aim of this study was to review the current status of clinical trials for HIV-associated malignancies in people living with HIV in sub-Saharan Africa (SSA) and efforts made by the AIDS Malignancy Consortium (AMC) to build capacity in SSA for HIV malignancy research.
All malignancy-related clinical trials in 49 SSA countries on ClinicalTrials.gov were reviewed and evaluated for inclusion and exclusion criteria pertaining to HIV status. Additional studies by AMC in SSA were compiled from Web-based resources, and narrative summaries were prepared to highlight AMC capacity building and training initiatives.
Of 96 cancer trials identified in SSA, only 11 focused specifically on people living with HIV, including studies in Kaposi sarcoma, cervical dysplasia and cancer, non-Hodgkin lymphoma, and ocular surface squamous neoplasia. Recognizing the increasing cancer burden in the region, AMC expanded its clinical trial activities to SSA in 2010, with 4 trials completed to date and 6 others in progress or development, and has made ongoing investments in developing research infrastructure in the region.
As the HIV-associated malignancy burden in SSA evolves, research into this domain has been limited. AMC, the only global HIV malignancy-focused research consortium, not only conducts vital HIV-associated malignancies research in SSA, but also develops pathology, personnel, and community-based infrastructure to meet these challenges in SSA. Nonetheless, there is an ongoing need to build on these efforts to improve HIV-associated malignancies outcomes in SSA.
本研究旨在回顾撒哈拉以南非洲（SSA）地区艾滋病毒感染者中与艾滋病毒相关恶性肿瘤的临床试验现状，以及艾滋病恶性肿瘤协会（AMC）为在SSA地区开展艾滋病毒恶性肿瘤研究能力建设所做的努力。
对ClinicalTrials.gov上49个SSA国家所有与恶性肿瘤相关的临床试验进行了回顾，并根据与艾滋病毒状况相关的纳入和排除标准进行了评估。从网络资源中收集了AMC在SSA地区开展的其他研究，并编写了叙述性总结，以突出AMC的能力建设和培训举措。
在SSA地区确定的96项癌症试验中，只有11项专门针对艾滋病毒感染者，包括卡波西肉瘤、宫颈发育异常和癌症、非霍奇金淋巴瘤以及眼表鳞状上皮瘤的研究。认识到该地区癌症负担日益加重，AMC于2010年将其临床试验活动扩展到SSA地区，迄今已完成4项试验，另有6项正在进行或处于开发阶段，并一直在投资发展该地区的研究基础设施。
随着SSA地区与艾滋病毒相关的恶性肿瘤负担不断变化，该领域的研究一直有限。AMC是唯一专注于全球艾滋病毒恶性肿瘤的研究联盟，不仅在SSA地区开展重要的与艾滋病毒相关的恶性肿瘤研究，还发展病理学、人员和基于社区的基础设施，以应对SSA地区的这些挑战。尽管如此，仍需要在这些努力的基础上继续改进SSA地区与艾滋病毒相关的恶性肿瘤治疗结果。
